Emory University Names Pilgrim Software as Clinical Trial Auditing Solution Provider

TAMPA, Fla.--(BUSINESS WIRE)--Pilgrim Software, Inc., a world-leading provider of Enterprise Risk, Compliance and Quality Management (ERCQM) software solutions, today announced that Emory University, a world-leading research university located in Atlanta, has selected Pilgrim to support its clinical trial internal auditing operations. Emory University's Clinical Trials Audit & Compliance Office will implement Pilgrim's Audit Management solution as its platform to manage regulatory and quality audits, improve the visibility of internal processes, and attain long-term strategic goals and objectives.

Emory will implement Pilgrim's Audit Management within its Academic Medical Center environment to manage the end-to-end process for clinical trial internal reviews. The solution will enable Emory to effectively conduct audit scheduling, audit execution and approvals, recording and issuance of observations and capture corrective action responses, and management reporting. Pilgrim's Audit Offline solution will allow Emory to perform remote audits as well while disconnected from the network. Audit results are merged in a single system, providing management greater visibility into the organization's performance.

With Audit and Audit Offline Management, Emory clinical trial auditors can track their actions in a structured and verifiable manner, and receive notifications and subsequent approvals, thereby increasing their accountability. Management will now be able to monitor audit processes and access data and reports on the university's clinical trial compliance standing, using Pilgrim's SmartInsightTM integrated reporting tool, which can be leveraged to take quick, effective and appropriate actions to prevent or correct problems.

"As a Top-20 research university and provider of one of the nation's best-known university healthcare systems, it is critical that Emory constantly ensures it is offering and using the highest quality and most advanced products, while remaining fully compliant with internal standards and external regulatory requirements," said Anne Adams, Interim Associate Vice President, Clinical Trials Compliance at Emory University.

"Our SmartAudit solution provides Emory with an electronic clinical trial audit management system that will help ensure regulatory compliance by providing audit efficiencies and meeting their specific audit needs," said Prashanth Rajendran, Pilgrim Software's Chief Operating Officer. "By automating its clinical trial audit processes, Emory will further enhance its respected reputation for quality and its distinction as one of the United States' most trusted and reliable medical and research institutions."

About Emory University

Emory University, a top 20 research university located in Atlanta, Georgia, is an inquiry-driven, ethically engaged and diverse community whose members work collaboratively for positive transformation in the world through courageous leadership in teaching, research, scholarship, health care and social action. The university is recognized internationally for its outstanding liberal arts college, superb professional schools and one of the Southeast's leading health care systems. Website: http://www.emory.edu

About Pilgrim Software, Inc.

Pilgrim Software, Inc. is a world-leading provider of Enterprise Risk, Compliance and Quality Management solutions for global organizations. Named North American Enterprise Compliance & Quality Management Company of the Year - Best Practices by Frost & Sullivan, Pilgrim helps organizations manage industry and regulatory compliance, reduce manufacturing costs and improve customer satisfaction. For more information, visit Pilgrim Software's website at www.pilgrimsoftware.com.

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.